Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future

Chimeric antigen receptor (CAR) T-cell therapy is the new standard treatment for various indications in patients with advanced hematologic malignancies. Despite the several preclinical and early phase clinical trials, the overall clinical experience has been disappointing when applying this innovati...

Descripción completa

Detalles Bibliográficos
Autores principales: Srour, Samer A., Akin, Serkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888521/
https://www.ncbi.nlm.nih.gov/pubmed/36751657
http://dx.doi.org/10.36401/JIPO-22-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888521/
https://www.ncbi.nlm.nih.gov/pubmed/36751657
http://dx.doi.org/10.36401/JIPO-22-7

Ejemplares similares